查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1847915

按药物类别、剂型、通路和最终用户分類的药物性失眠治疗市场—2025-2032年全球预测

Insomnia Pharmacological Treatment Market by Drug Class, Dosage Form, Distribution Channel, End User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 197 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，失眠药物治疗市场将成长至 123.7 亿美元，复合年增长率为 7.34%。

主要市场统计数据
基准年 2024 70.1亿美元
预计年份：2025年 75.2亿美元
预测年份：2032年 123.7亿美元
复合年增长率 (%) 7.34%

一个全面的失眠药物治疗策略框架，旨在平衡临床疗效、安全性权衡、患者异质性以及不断变化的治疗优先事项。

失眠症仍然是一个复杂的临床挑战，涉及神经病学、精神病学、基层医疗和公共卫生等多个领域。药物治疗仍然是许多患者的核心治疗手段，尤其是在单纯行为介入无法提供充分缓解的情况下。因此，临床医生在选择治疗方案时需要权衡疗效、安全性、成瘾风险和日间功能，而支付者和管理人员则需要考虑处方笺分配和长期依从性。因此，治疗方法通常包含多种药物类别，以针对不同的病理学标靶并满足患者的偏好。

近年来，镇静催眠药的使用逐渐从传统的老药转向耐受性较好、作用机转较佳的药物。这种转变反映了监管机构对某些苯二氮平类药物长期使用的审查力度加大，以及人们对Orexin受体拮抗剂和褪黑素受体促效剂兴趣的日益增长。同时，由于镇静抗忧郁症在治疗合併情绪障碍和失眠方面具有双重潜力，因此它们被广泛用于仿单标示外。

临床实践越来越重视根据睡眠结构、合併症和患者生活方式量身定制的个人化治疗方案。因此，製药公司和医疗保健系统目前正致力于研发差异化製剂、改进包装以提高患者依从性，并进行真实世界疗效研究。简而言之，失眠的药物治疗正进入一个新阶段，治疗方案的选择不仅要关注改善夜间睡眠质量，还要兼顾安全性和日常功能。

再形成失眠药物的关键变化融合了分子创新、注重实际应用的监管以及数位化医疗模式。

由于科学进步、法规演变和医疗服务模式转变，失眠治疗领域正在经历变革性变化。首先，分子生物学创新使人们更加关注除γ-氨基丁酸（GABA）调节以外的其他机制，其中Orexin受体拮抗剂作为一种直接作用于觉醒迴路的有效替代方案而脱颖而出。同时，褪黑素受体促效剂的改进和製剂工程的进步，透过缓释技术调节了失眠的发生和维持。

同时，商业性动态正迫使製造商重新评估其生命週期策略。专利到期和学名药上市加剧了竞争，推动了对高附加价值製剂、联合治疗以及针对特定患者群体的扩展适应症的投资。与药物创新相辅相成的是，数位疗法和远端监测工具已成为日常辅助手段，使临床医生能够追踪睡眠模式并更快地调整药物治疗。

法律规范也在发生变化，更加强调上市后安全性监测和真实世界证据，以指导标籤标註和风险缓解。这种监管力度的加强正在加速观察性资料流和可操作性临床试验的应用，以了解长期疗效。总而言之，这些转变创造了一个更细緻入微、以证据为导向的环境，在这个环境中，产品差异化不仅取决于睡眠指标，还取决于患者功能、耐受性和依从性的显着改善。

2025年近期贸易政策的变化如何改变了失眠治疗供应链网络的供应链策略、采购动态和价格压力

2025年关税及贸易调整措施为失眠药物的生产和分销供应链带来了重大曲折点。依赖国际采购的活性药物原料药和辅料的製造商立即面临成本压力，促使他们重新评估供应商布局和合约条款。为此，许多公司加快了供应商多元化步伐，提高了安全库存水平，并寻求近岸生产方案，以降低跨境关税波动带来的风险。

这些变化也影响了医院、药局和专科诊所的筹资策略，促使它们加强库存管理，并重新重视供应商合格。支付方和合约机构展开了更深入的谈判，以抵消潜在的价格影响；药品福利管理机构重新评估了处方笺目录，以确保患者的用药负担能力。同时，经销商也调整了物流计划，以减少因新关税分类而导致的运输延误和合规成本。

从策略角度来看，关税促使企业重新投资于供应链韧性和成本服务模式。企业优先考虑与地域分散的供应商签订长期合同，并投资于流程改进以抵消利润率下降的影响。因此，相关人员采取了一种更为全面的製造经济观点，将监管合规、贸易政策风险以及确保药品送达患者的实际运作纳入考量。

深入的分析揭示了治疗层级、剂型影响、分销管道的作用以及最终用户护理路径要求等方面的细微差别。

对细分市场的深入理解对于制定满足临床医生期望和患者需求的产品策略至关重要。经典的苯二氮平类药物，如艾司唑仑、替马西泮和三唑仑，因其快速起效、强效的催眠作用，仍被需要的患者广泛使用，但其成瘾性和认知方面的副作用需要谨慎管理。褪黑素受体激动剂，如Agomelatine、褪黑素和雷美替胺，因其能够调节昼夜节律且耐受性良好，尤其适用于昼夜节律紊乱的患者，而备受临床医生的青睐。非苯二氮平类促效剂，如Eszopiclone、Zaleplon和Zolpidem，因其在诱导和维持睡眠方面的有效性而仍然十分重要，其中Zolpidem有缓释性和即时释两种剂型，可实现个体化的给药方案。Orexin受体拮抗剂，例如伦博雷生和苏沃雷生，其作用机制正转向抑制觉醒，这反映在专科医师的处方模式中。当合併情绪或焦虑障碍使睡眠管理复杂化时，镇静性抗忧郁症，例如多塞平和曲唑酮，仍被用作治疗手段。

剂型细分会影响患者的用药依从性和临床效用。胶囊，无论是硬胶囊或软胶囊，都便于服用，且因其生物有效性而常被选用。片剂分为控制释放片和即时释片，使临床医师能够针对特定睡眠阶段给药，并平衡起效时间和持续时间。剂型与药物动力学之间的相互作用仍然是选择治疗方案的关键因素。

分销管道细分决定了产品如何触及患者以及哪些价值提案最为重要。公立和私立医院药房优先考虑处方笺稳定性和住院安全，而线上药房（无论是大众市场药房还是专科线上药房）则强调便利性、持续性护理和处方笺处理效率。零售药房分为连锁药房和独立药房，它们在便利性和个人化咨询之间寻求平衡，从而影响患者的用药依从性和品牌忠诚度。

终端用户细分能够捕捉不同的护理管道和服务需求。居家照护机构，包括辅助生活设施和私人居家护理，需要简化的用药方案、清晰的看护者指导以及能够减少用药错误的包装。综合医院和精神病院都需要能够与急性护理方案相整合并最大限度减少药物交互作用的药物。专科诊所，例如门诊中心和睡眠障碍诊所，则专注于精准治疗和监测，以优化夜间睡眠结构和日间功能。了解这些相互依存的细分市场，有助于制定有针对性的产品设计、管道策略和临床证据项目，从而将治疗方案与实际应用情境相匹配。

以主要全球市场为例，对采用模式、法规细微差别、生产布局和分销动态进行比较区域分析

区域动态显着影响失眠治疗药物的研发、核准、分销和应用。在美洲，製剂研发者的偏好和支付机制通常倾向于快速获得创新药物，而成本控制措施和复方谈判则影响长期用药模式。在北美临床实践中，针对日间功能的新型治疗方法的应用正在增加，而远端医疗的整合也为专科医生提供了更多服务社区的机会。

在欧洲、中东和非洲，监管差异和医疗保健资金筹措模式的多样性造成了不同地区的采用率差异。在一些欧洲市场，严格的疗效比较评估和卫生技术评估被纳入报销决策，这要求製造商提供证据并符合当地的价值框架。同时，在一些中东和非洲市场，私营部门的采用速度正在加快，私立医院和专科诊所正在推动差异化治疗方法的早期应用。

亚太地区既是製造业中心，也是充满活力的市场，各国临床实务各有不同。学名药产量庞大，而睡眠医学专家高度集中的都市区对新型药物的需求旺盛。数位医疗在亚太部分地区迅速普及，推动了将药物治疗与远距监测和行为介入相结合的混合医疗模式的发展。因此，每个地区的具体情况都需要量身定制的监管沟通计画、供应链规划和商业策略，这些都需要考虑到当地临床医生的偏好、支付方结构和分销管道的优势。

策略性企业行动指南概述了投资组合多元化、供应链韧性、生命週期管理和数位化伙伴关係，以增强失眠治疗效果。

主要企业正采用多管齐下的策略来保持竞争力并提供临床价值。产品系列多元化是重中之重，各公司在保留现有药物的同时，也投资于下一代作用机制和製剂改进。许可和策略联盟能够加速新型化合物的获取，并以外部创新补充内部研发能力。

在营运方面，製造商正专注于建立具有韧性的供应链，并遵循品质源自设计的原则，以降低贸易和生产风险。与受託製造厂商和原料药供应商建立策略联盟，既能确保产能，又能实现灵活的规模化生产。在商业方面，随着学名药进入市场，製造商正积极推行生命週期管理策略（缓释性、复方製剂、扩大适应症等），以实现差异化竞争。

此外，企业正日益整合数位健康伙伴关係，利用依从性工具、睡眠追踪器、临床医师仪表板等来增强药物治疗效果。此类组合不仅有助于提高患者参与度，还能产生真实世界证据，从而在与支付方的讨论中凸显产品价值。併购仍然是获取在研产品、分销管道和治疗领域专业知识以加速市场进入和扩大商业性覆盖范围的战术性策略。

针对製造商、支付者和医疗保健提供者，提出切实可行的高优先建议，以优化失眠治疗产品的价值、供应链的稳定性以及以患者为中心的治疗效果。

产业领导者应优先采取实际行动，将临床差异化与永续的商业模式结合。首先，应投资于能够展现功能性结果的临床项目，例如日间表现和认知安全性，以及夜间指标。这些数据将增强对支付方和製剂生产商的价值提案。同时，应拓展控制释放和软胶囊的选择范围，并加速製剂创新，以提高老年人和多重用药族群的用药依从性。

在供应方面，我们将对关键原料药实施多通路采购策略，并建立紧急生产协议以应对贸易中断的影响。我们将积极与采购和支付相关人员沟通，制定风险分担和管理准入协议，在应对成本压力的同时，确保药物供应。同时，我们将与数位疗法提供者建立伙伴关係，整合药物和行为介入措施，从而改善长期疗效并支持真实世界证据的产生。

在商业性，我们将根据当地市场动态调整通路策略：加强与医疗机构医院处方集委员会的关係，优化线上药局通路的电履约，并支援独立零售合作伙伴的定向教育和用药依从性计画。最后，我们将与监管机构保持持续的沟通，利用上市后数据和可操作的研究成果，调整不同地区的药品标籤，并支持新市场准入。

采用稳健的混合方法研究途径，结合临床医师访谈、病患见解、监管审查和资料三角验证，以产生有效的失眠治疗市场观点。

本分析的调查方法采用严谨的混合方法，以确保其可靠性和有效性。主要研究包括对睡眠医学专家、精神科医生、药剂师、医院製剂人员和行业高管进行结构化访谈和定性讨论，以了解临床实践模式、采购行为和战略重点。来自患者和看护者的回馈探讨了依从性和耐受性，这些因素会影响实际疗效。

二级研究利用同侪审查文献、监管指导文件、临床试验註册库和药品品质标准来检验作用机制和安全性数据。竞争情报流程整合了已发表的文件、专利文献和产品标籤，绘製了产品组合策略和生命週期事件图。数据三角测量技术协调了不同的输入讯息，并强调了独立来源之间的一致性。

分析方法包括对定性输入进行主题编码，以及采用比较框架评估产品和通路属性。限制包括各地区纵向真实世界数据的可用性有限，以及配方指南的异质性。为减少偏差，本研究与多位专家进行了交叉验证，并记录了资料来源以确保结果的可重复性。所有关键互动均遵循伦理考量和资料保护标准，匿名报告则保护了受访者的隐私。

简洁扼要的结论，整合了临床创新、营运韧性和市场需求，以指南失眠药物治疗的策略行动。

失眠的药物治疗正处于曲折点特定机制的创新、不断发展的分销管道以及供应链的韧性正在共同塑造未来的治疗模式。临床医师越来越倾向于选择不仅能改善夜间睡眠指标，还能维持日间功能和认知功能的治疗方法。因此，Orexin受体拮抗剂、纯化褪黑素促效剂以及各种差异化製剂正日益受到临床和商业性的重视。

同时，不断变化的贸易政策和来自学名药的竞争压力迫使企业采取整体策略，整合可靠的证据产生、灵活的供应链设计和精准的商业化策略。区域差异和多样化的分销管道要求企业制定符合监管预期和支付方动态的区域参与计画。最终，那些将严谨的临床项目与务实的营运措施相结合的相关人员，将更有能力为患者和医疗保健系统创造可持续的价值。

透过优先考虑高品质的结果数据，投资于以患者为中心的配方和支援服务，并加强供应链以应对政策和市场波动，医疗保健相关人员可以满足失眠患者的复杂需求，同时保持商业性可行性和临床信誉。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

  • 双重Orexin受体拮抗剂作为慢性失眠第一线治疗药物的出现
  • 低剂量褪黑激素受体促效剂在老年失眠患者的应用日益广泛
  • 一项新型GABA-A正向变构调节因子改善睡眠维持的临床研究结果
  • 针对失眠症夜间觉醒的缓释性的研发
  • 整合药物基因组学分析以实现失眠治疗方案的个人化选择
  • 扩大非处方镇静催眠药的选择范围及其对剂量的影响
  • 临床实务中，越来越多的失眠药物治疗合併使用数位化依从性监测。

第六章美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

8. 依药物类别分類的失眠药物治疗市场

  • 苯二氮平类药物
    • 艾司唑仑
    • 替马西泮
    • 三唑仑
  • 褪黑素受体促效剂
    • Agomelatine
    • 褪黑素
    • 拉美利提翁
  • 非苯二氮平类催眠药
    • Eszopiclone
    • Zaleplon
    • Zolpidem
      • 加长版
      • 即时发布
  • Orexin受体拮抗剂
    • 伦博雷桑
    • 苏沃雷桑
  • 镇静性抗忧郁症
    • 多塞平
    • 曲唑酮

9. 按剂型分類的失眠药物治疗市场

  • 胶囊
    • 硬明胶
    • 软明胶
  • 口服悬浮液
  • 药片
    • 控释
    • 即时发布

10. 按分销管道分類的失眠药物治疗市场

  • 医院药房
    • 私人的
    • 公共
  • 网路药房
    • 市场
    • 专业网路药房
  • 零售药房
    • 链
    • 独立

第十一章 以最终用户分類的失眠药物治疗市场

  • 居家照护
    • 辅助生活设施
    • 私人居家医疗
  • 医院
    • 综合医院
    • 精神病院
  • 专科诊所
    • 门诊部
    • 睡眠障碍诊所

12. 各地区药物治疗失眠市场

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章 失眠药物治疗市场（按组别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

14. 各国药物治疗失眠市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十五章 竞争格局

  • 2024年市占率分析
  • FPNV定位矩阵，2024
  • 竞争分析
    • Merck & Co., Inc.
    • Eisai Co., Ltd.
    • Idorsia Pharmaceuticals Ltd.
    • Pfizer Inc.
    • Teva Pharmaceutical Industries Ltd.
    • Viatris Inc.
    • Novartis AG
    • Aa Pharma Inc.
    • Eisai Co., Ltd.
    • Makers Nutrition, LLC
Product Code: MRR-FB6C9E792FEB

The Insomnia Pharmacological Treatment Market is projected to grow by USD 12.37 billion at a CAGR of 7.34% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 7.01 billion
Estimated Year [2025] USD 7.52 billion
Forecast Year [2032] USD 12.37 billion
CAGR (%) 7.34%

A comprehensive framing of pharmacological strategies for insomnia that balances clinical efficacy, safety trade-offs, patient heterogeneity, and evolving therapeutic priorities

Insomnia persists as a complex clinical challenge that intersects neurology, psychiatry, primary care, and public health. Pharmacological treatment remains a central pillar for many patients, particularly where behavioral interventions alone fail to deliver sufficient relief. Clinicians therefore balance efficacy, safety, dependency risk, and daytime functioning when selecting therapeutics, while payers and administrators factor in formulary placement and long-term adherence. As a result, the therapeutic landscape comprises multiple drug classes that address diverse pathophysiological targets and patient preferences.

Recent years have seen a migration from older sedative-hypnotics toward agents that offer improved tolerability profiles and targeted mechanisms. This shift reflects growing regulatory scrutiny over long-term use of certain benzodiazepines and a parallel rise in interest in orexin receptor antagonists and melatonin receptor agonists. Meanwhile, sedating antidepressants remain widely used off-label due to their dual therapeutic effects for comorbid mood disorders and insomnia, which underscores the importance of integrated care pathways.

Clinical practice increasingly emphasizes personalized regimens aligned with sleep architecture, comorbidities, and patient lifestyle. Consequently, pharmaceutical manufacturers and health systems now focus on differentiated formulations, adherence-supporting packaging, and real-world outcomes research. In short, pharmacological management of insomnia is entering a phase in which therapeutic selection is as much about aligning safety and daily functioning as it is about improving nocturnal sleep measures.

Key transformative changes reshaping insomnia pharmacotherapy that combine molecular innovation, regulatory real-world emphasis, and digitally enabled care models

The landscape of insomnia treatment is undergoing transformative shifts driven by scientific advances, regulatory evolution, and changing care delivery models. First, molecular innovation has prioritized mechanisms beyond gamma-aminobutyric acid modulation, with orexin receptor antagonists emerging as a notable alternative that addresses wakefulness circuitry directly. Concurrently, refinements in melatonin receptor agonists and formulation engineering have sought to reconcile onset and maintenance insomnia through modified-release technologies.

At the same time, commercial dynamics have compelled manufacturers to rethink lifecycle strategies. Patent expirations and generic entry have heightened competition, stimulating investment in value-added formulations, combination approaches, and label expansions that target specific patient cohorts. Parallel to pharmacologic innovation, digital therapeutics and remote monitoring tools have become routine adjuncts, enabling clinicians to track sleep patterns and adjust pharmacotherapy more responsively.

Regulatory frameworks have also shifted, with agencies emphasizing post-marketing safety surveillance and real-world evidence to inform labeling and risk mitigation. This regulatory focus has accelerated the adoption of observational data streams and pragmatic clinical trials to capture long-term outcomes. Taken together, these shifts have created a more nuanced, evidence-driven environment where product differentiation hinges on demonstrable improvements in patient functioning, tolerability, and adherence rather than sleep metrics alone.

How recent trade policy shifts in 2025 have reshaped supply chain strategies, procurement dynamics, and pricing pressures across insomnia pharmacological supply networks

The imposition of tariffs and trade adjustments in 2025 created a material inflection point for supply chains that support insomnia pharmacological manufacturing and distribution. Manufacturers that rely on internationally sourced active pharmaceutical ingredients and excipients experienced immediate cost pressures, catalyzing re-evaluations of supplier footprints and contractual terms. In response, many organizations accelerated supplier diversification, increased safety stock levels, and pursued near-shore manufacturing options to reduce exposure to cross-border tariff volatility.

These changes had downstream effects on procurement strategies within hospitals, pharmacies, and specialty clinics, prompting tighter inventory management and renewed emphasis on supplier qualification. Payers and contracting entities engaged in more intensive negotiations to offset potential price impacts, while pharmacy benefit managers revisited formulary placements to preserve affordability for patients. In parallel, distributors recalibrated logistics planning to mitigate transit delays and compliance costs associated with new tariff classifications.

Strategically, the tariffs prompted renewed investment in supply chain resilience and cost-to-serve modeling. Companies prioritized long-term agreements with geographically diversified suppliers and invested in process improvements to offset margin compression. Consequently, stakeholders adopted a more holistic view of manufacturing economics that integrates regulatory compliance, trade policy risk, and the operational realities of getting medications to patients reliably.

In-depth segmentation-driven insights revealing therapeutic class nuances, dosage form implications, distribution channel roles, and end user care pathway requirements

A nuanced understanding of market segments is essential to design product strategies that meet clinician expectations and patient needs. Drug class segmentation underscores divergent therapeutic priorities: classic benzodiazepines such as estazolam, temazepam, and triazolam continue to serve patients who need rapid onset and strong hypnotic effects, yet they prompt careful stewardship due to dependency and cognitive side effect profiles. Melatonin receptor agonists, including agomelatine, melatonin, and ramelteon, appeal to clinicians seeking circadian alignment and favorable tolerability, especially for patients with circadian rhythm disturbances. Non-benzodiazepine hypnotics like eszopiclone, zaleplon, and zolpidem remain important for their efficacy in sleep initiation and maintenance, with zolpidem available in both extended-release and immediate-release formats to tailor dosing strategies. Orexin receptor antagonists such as lemborexant and suvorexant represent a mechanistic shift toward wakefulness inhibition, which has resonated in specialist prescribing patterns. Sedating antidepressants, notably doxepin and trazodone, persist in therapeutic arsenals when comorbid mood or anxiety disorders complicate sleep management.

Dosage form segmentation shapes both adherence and clinical utility. Capsules, whether hard gelatin or soft gelatin, offer convenient dosing and are often chosen for bioavailability considerations, whereas oral suspensions provide dosing flexibility for pediatric or geriatric cohorts. Tablets, in controlled-release or immediate-release formats, enable clinicians to target specific sleep phases and balance onset with duration. The interplay between form and pharmacokinetics remains a decisive factor in regimen selection.

Distribution channel segmentation determines how products reach patients and which value propositions matter most. Hospital pharmacies in private and public settings prioritize formulary stability and inpatient safety, while online pharmacies, whether large marketplaces or specialty online providers, emphasize convenience, continuity of care, and prescription fulfillment efficiencies. Retail pharmacies, split between chain and independent operators, balance accessibility with personalized counseling, influencing adherence and brand loyalty.

End user segmentation captures divergent care pathways and service requirements. Homecare settings, including assisted living and private homecare, demand simplified regimens, clear caregiver instructions, and packaging that reduces dosing errors. Hospitals, both general and psychiatric, require medications that integrate with acute care protocols and minimize drug-drug interactions. Specialty clinics, such as outpatient centers and dedicated sleep disorder clinics, focus on precision therapies and monitoring to optimize nocturnal architecture and daytime functioning. Understanding these interdependent segments enables targeted product design, channel strategies, and clinical evidence programs that align therapeutic attributes with real-world use cases.

Comparative regional analysis highlighting adoption patterns, regulatory nuances, manufacturing footprints, and distribution dynamics across major global markets

Regional dynamics materially influence how insomnia therapies are developed, approved, distributed, and adopted. In the Americas, prescriber preferences and payer mechanisms often favor rapid access to innovative agents, while cost containment measures and formulary negotiations shape long-term utilization patterns. North American clinical practice has shown notable uptake of newer mechanisms that emphasize daytime functioning, and integration of telehealth has increased specialist reach into community settings.

In Europe, Middle East & Africa, regulatory heterogeneity and diverse healthcare funding models create a mosaic of adoption rates. In several European markets, rigorous comparative effectiveness assessments and health technology appraisals inform reimbursement decisions, prompting manufacturers to align evidence generation with local value frameworks. Meanwhile, certain Middle Eastern and African markets exhibit accelerated private sector uptake where private hospitals and specialty clinics can drive early utilization of differentiated therapies.

The Asia-Pacific region serves both as a manufacturing hub and a dynamic market with varied clinical practices across countries. High-volume generic production coexists with strong demand for novel mechanisms in urban centers where sleep medicine specialties concentrate. Rapid digital health adoption in parts of Asia-Pacific has facilitated hybrid care models that combine pharmacotherapy with remote monitoring and behavioral interventions. Each regional context therefore requires a tailored regulatory engagement plan, supply chain mapping, and commercial strategy that accounts for local clinician preferences, payer structures, and distribution channel strengths.

Strategic corporate playbook outlining portfolio diversification, supply chain resilience, lifecycle management, and digital partnerships to strengthen insomnia treatment offerings

Leading companies in the insomnia pharmacotherapy space are adopting multi-pronged strategies to sustain competitiveness and deliver clinical value. Product portfolio diversification ranks highly, with firms maintaining legacy agents while investing in next-generation mechanisms and formulation enhancements. Licensing arrangements and strategic collaborations accelerate access to novel compounds and complement internal R&D capabilities with external innovation.

Operationally, manufacturers emphasize resilient supply chains and quality-by-design principles to mitigate trade and manufacturing risks. Strategic alliances with contract manufacturing organizations and API suppliers help secure capacity while enabling agile scale-up. Commercially, companies pursue lifecycle management strategies-such as extended-release formulations, fixed-dose combinations, and indication expansions-to differentiate offerings as generics enter the market.

Moreover, a growing number of firms are integrating digital health partnerships to augment pharmacotherapy with adherence tools, sleep trackers, and clinician dashboards. These combinations not only support patient engagement but also generate real-world evidence to underscore product value in payer discussions. Mergers and acquisitions continue to be a tactical route for acquiring pipeline assets, distribution footprints, and therapeutic expertise that accelerate market access and broaden commercial reach.

Practical and prioritized recommendations for manufacturers, payers, and providers to optimize product value, supply resilience, and patient-centered outcomes in insomnia care

Industry leaders should prioritize concrete actions that align clinical differentiation with sustainable commercial models. First, invest in clinical programs that demonstrate functional outcomes such as daytime performance and cognitive safety in addition to nocturnal measures; these data will strengthen value propositions with payers and prescribers. Simultaneously, accelerate formulation innovation by expanding controlled-release and soft gelatin capsule options to improve adherence across geriatric and polypharmacy populations.

On the supply side, implement multi-sourcing strategies for key APIs and establish contingency manufacturing agreements to buffer trade-related disruptions. Engage proactively with procurement and payer stakeholders to design risk-sharing and managed-entry agreements that preserve access while addressing cost pressures. In parallel, forge partnerships with digital therapeutics providers to bundle pharmacologic and behavioral interventions, thereby enhancing long-term outcomes and supporting real-world evidence generation.

Commercially, tailor channel strategies to local market dynamics: strengthen relationships with hospital formulary committees in institutional settings, optimize e-commerce fulfillment for online pharmacy channels, and support independent retail partners with targeted education and adherence programs. Finally, maintain an iterative regulatory engagement plan that leverages post-marketing data and pragmatic studies to adapt labeling and support market access across diverse geographies.

Robust mixed-methods research approach combining clinician interviews, patient insights, regulatory review, and data triangulation to produce validated insomnia drug market perspectives

The research methodology underpinning this analysis combined a rigorous mixed-methods approach to ensure credibility and relevance. Primary research included structured interviews and qualitative discussions with sleep medicine specialists, psychiatrists, pharmacists, hospital formulary decision-makers, and industry executives to capture clinical practice patterns, procurement behaviors, and strategic priorities. Patient and caregiver feedback informed adherence and tolerability considerations that influence real-world effectiveness.

Secondary research leveraged peer-reviewed literature, regulatory guidance documents, clinical trial registries, and pharmaceutical quality standards to validate mechanistic claims and safety profiles. Competitive intelligence processes synthesized public filings, patent literature, and product labeling to map portfolio strategies and lifecycle events. Data triangulation techniques reconciled divergent inputs and emphasized convergence across independent sources.

Analytical methods incorporated thematic coding for qualitative inputs and comparative frameworks to assess product and channel attributes. Limitations included variable availability of longitudinal real-world data across regions and heterogeneity in prescribing guidelines. To mitigate bias, the research applied cross-validation with multiple expert respondents and documented source provenance for reproducibility. Ethical considerations and data protection standards guided all primary interactions, and anonymized reporting protected respondent confidentiality.

Concise conclusion synthesizing clinical innovation, operational resilience, and market imperatives to guide strategic action in insomnia pharmacological care

The pharmacological management of insomnia stands at an inflection point where mechanism-specific innovation, distribution evolution, and supply chain resilience converge to shape future care paradigms. Clinicians increasingly favor therapeutics that not only improve nocturnal sleep metrics but also preserve daytime functioning and cognitive safety. Consequently, orexin receptor antagonists, refined melatonin agonists, and differentiated formulations have assumed greater clinical and commercial importance.

At the same time, trade policy shifts and competitive generic pressures compel organizations to adopt holistic strategies that integrate robust evidence generation, agile supply chain design, and targeted commercialization tactics. Regional heterogeneity and diverse distribution channels necessitate localized engagement plans that respect regulatory expectations and payer dynamics. Ultimately, stakeholders that align rigorous clinical programs with pragmatic operational measures will be best positioned to deliver sustainable value to patients and healthcare systems.

Moving from insight to impact requires deliberate execution: prioritize high-quality outcomes data, invest in patient-centric formulation and support services, and fortify supply chains against policy and market volatility. Doing so will enable healthcare stakeholders to meet the complex needs of patients living with insomnia while maintaining commercial viability and clinical credibility.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Emergence of dual orexin receptor antagonists as first line therapy for chronic insomnia
  • 5.2. Increasing adoption of low-dose melatonin receptor agonists for elderly insomnia patients
  • 5.3. Clinical trial results for novel GABA-A positive allosteric modulators improving sleep maintenance
  • 5.4. Development of extended release formulations targeting middle of the night awakening in insomnia
  • 5.5. Integration of pharmacogenomic profiling to personalize insomnia medication selection
  • 5.6. Expansion of over-the-counter sedative-hypnotic options and its impact on prescription volumes
  • 5.7. Rising use of digital adherence monitoring combined with insomnia pharmacotherapy in clinical practice

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Insomnia Pharmacological Treatment Market, by Drug Class

  • 8.1. Benzodiazepines
    • 8.1.1. Estazolam
    • 8.1.2. Temazepam
    • 8.1.3. Triazolam
  • 8.2. Melatonin Receptor Agonists
    • 8.2.1. Agomelatine
    • 8.2.2. Melatonin
    • 8.2.3. Ramelteon
  • 8.3. Non Benzodiazepine Hypnotics
    • 8.3.1. Eszopiclone
    • 8.3.2. Zaleplon
    • 8.3.3. Zolpidem
      • 8.3.3.1. Extended Release
      • 8.3.3.2. Immediate Release
  • 8.4. Orexin Receptor Antagonists
    • 8.4.1. Lemborexant
    • 8.4.2. Suvorexant
  • 8.5. Sedating Antidepressants
    • 8.5.1. Doxepin
    • 8.5.2. Trazodone

9. Insomnia Pharmacological Treatment Market, by Dosage Form

  • 9.1. Capsules
    • 9.1.1. Hard Gelatin
    • 9.1.2. Soft Gelatin
  • 9.2. Oral Suspension
  • 9.3. Tablets
    • 9.3.1. Controlled Release
    • 9.3.2. Immediate Release

10. Insomnia Pharmacological Treatment Market, by Distribution Channel

  • 10.1. Hospital Pharmacy
    • 10.1.1. Private
    • 10.1.2. Public
  • 10.2. Online Pharmacy
    • 10.2.1. Marketplaces
    • 10.2.2. Specialty Online Pharmacies
  • 10.3. Retail Pharmacy
    • 10.3.1. Chain
    • 10.3.2. Independent

11. Insomnia Pharmacological Treatment Market, by End User

  • 11.1. Homecare Settings
    • 11.1.1. Assisted Living
    • 11.1.2. Private Homecare
  • 11.2. Hospitals
    • 11.2.1. General Hospitals
    • 11.2.2. Psychiatric Hospitals
  • 11.3. Specialty Clinics
    • 11.3.1. Outpatient Clinics
    • 11.3.2. Sleep Disorder Clinics

12. Insomnia Pharmacological Treatment Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Insomnia Pharmacological Treatment Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Insomnia Pharmacological Treatment Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2024
  • 15.2. FPNV Positioning Matrix, 2024
  • 15.3. Competitive Analysis
    • 15.3.1. Merck & Co., Inc.
    • 15.3.2. Eisai Co., Ltd.
    • 15.3.3. Idorsia Pharmaceuticals Ltd.
    • 15.3.4. Pfizer Inc.
    • 15.3.5. Teva Pharmaceutical Industries Ltd.
    • 15.3.6. Viatris Inc.
    • 15.3.7. Novartis AG
    • 15.3.8. Aa Pharma Inc.
    • 15.3.9. Eisai Co., Ltd.
    • 15.3.10. Makers Nutrition, LLC

LIST OF FIGURES

  • FIGURE 1. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY DRUG CLASS, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY DOSAGE FORM, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY DOSAGE FORM, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. AMERICAS INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. NORTH AMERICA INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. LATIN AMERICA INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. EUROPE, MIDDLE EAST & AFRICA INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. EUROPE INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. MIDDLE EAST INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. AFRICA INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASEAN INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GCC INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. EUROPEAN UNION INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. BRICS INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. G7 INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. NATO INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 28. INSOMNIA PHARMACOLOGICAL TREATMENT MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY BENZODIAZEPINES, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY BENZODIAZEPINES, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY BENZODIAZEPINES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY BENZODIAZEPINES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY BENZODIAZEPINES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY BENZODIAZEPINES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY BENZODIAZEPINES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY BENZODIAZEPINES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY ESTAZOLAM, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY ESTAZOLAM, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY ESTAZOLAM, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY ESTAZOLAM, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY ESTAZOLAM, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY ESTAZOLAM, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY TEMAZEPAM, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY TEMAZEPAM, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY TEMAZEPAM, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY TEMAZEPAM, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY TEMAZEPAM, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY TEMAZEPAM, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY TRIAZOLAM, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY TRIAZOLAM, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY TRIAZOLAM, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY TRIAZOLAM, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY TRIAZOLAM, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY TRIAZOLAM, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY MELATONIN RECEPTOR AGONISTS, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY MELATONIN RECEPTOR AGONISTS, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY MELATONIN RECEPTOR AGONISTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY MELATONIN RECEPTOR AGONISTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY MELATONIN RECEPTOR AGONISTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY MELATONIN RECEPTOR AGONISTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY MELATONIN RECEPTOR AGONISTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY MELATONIN RECEPTOR AGONISTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY AGOMELATINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY AGOMELATINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY AGOMELATINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY AGOMELATINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY AGOMELATINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY AGOMELATINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY MELATONIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY MELATONIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY MELATONIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY MELATONIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY MELATONIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY MELATONIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY RAMELTEON, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY RAMELTEON, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY RAMELTEON, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY RAMELTEON, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY RAMELTEON, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY RAMELTEON, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY NON BENZODIAZEPINE HYPNOTICS, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY NON BENZODIAZEPINE HYPNOTICS, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY NON BENZODIAZEPINE HYPNOTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY NON BENZODIAZEPINE HYPNOTICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY NON BENZODIAZEPINE HYPNOTICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY NON BENZODIAZEPINE HYPNOTICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY NON BENZODIAZEPINE HYPNOTICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY NON BENZODIAZEPINE HYPNOTICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY ESZOPICLONE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY ESZOPICLONE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY ESZOPICLONE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY ESZOPICLONE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY ESZOPICLONE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY ESZOPICLONE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY ZALEPLON, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY ZALEPLON, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY ZALEPLON, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY ZALEPLON, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY ZALEPLON, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY ZALEPLON, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY ZOLPIDEM, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY ZOLPIDEM, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY ZOLPIDEM, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY ZOLPIDEM, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY ZOLPIDEM, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY ZOLPIDEM, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY ZOLPIDEM, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY ZOLPIDEM, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY EXTENDED RELEASE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY EXTENDED RELEASE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY EXTENDED RELEASE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY EXTENDED RELEASE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY EXTENDED RELEASE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY EXTENDED RELEASE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY IMMEDIATE RELEASE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY IMMEDIATE RELEASE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY IMMEDIATE RELEASE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY IMMEDIATE RELEASE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY IMMEDIATE RELEASE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY IMMEDIATE RELEASE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY OREXIN RECEPTOR ANTAGONISTS, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY OREXIN RECEPTOR ANTAGONISTS, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY OREXIN RECEPTOR ANTAGONISTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY OREXIN RECEPTOR ANTAGONISTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY OREXIN RECEPTOR ANTAGONISTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY OREXIN RECEPTOR ANTAGONISTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY OREXIN RECEPTOR ANTAGONISTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY OREXIN RECEPTOR ANTAGONISTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY LEMBOREXANT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY LEMBOREXANT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY LEMBOREXANT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY LEMBOREXANT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY LEMBOREXANT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY LEMBOREXANT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY SUVOREXANT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY SUVOREXANT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY SUVOREXANT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY SUVOREXANT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY SUVOREXANT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY SUVOREXANT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY SEDATING ANTIDEPRESSANTS, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY SEDATING ANTIDEPRESSANTS, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY SEDATING ANTIDEPRESSANTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY SEDATING ANTIDEPRESSANTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY SEDATING ANTIDEPRESSANTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY SEDATING ANTIDEPRESSANTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY SEDATING ANTIDEPRESSANTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY SEDATING ANTIDEPRESSANTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY DOXEPIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY DOXEPIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY DOXEPIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY DOXEPIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY DOXEPIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY DOXEPIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY TRAZODONE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY TRAZODONE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY TRAZODONE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY TRAZODONE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY TRAZODONE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY TRAZODONE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY CAPSULES, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY CAPSULES, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY CAPSULES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY CAPSULES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY CAPSULES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY CAPSULES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY CAPSULES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY CAPSULES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY HARD GELATIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY HARD GELATIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY HARD GELATIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY HARD GELATIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY HARD GELATIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY HARD GELATIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY SOFT GELATIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY SOFT GELATIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY SOFT GELATIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY SOFT GELATIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY SOFT GELATIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY SOFT GELATIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY ORAL SUSPENSION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY ORAL SUSPENSION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY ORAL SUSPENSION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY ORAL SUSPENSION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY ORAL SUSPENSION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY ORAL SUSPENSION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY TABLETS, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY TABLETS, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY TABLETS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY TABLETS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY TABLETS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY TABLETS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY TABLETS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY TABLETS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY CONTROLLED RELEASE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY CONTROLLED RELEASE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY CONTROLLED RELEASE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY CONTROLLED RELEASE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY CONTROLLED RELEASE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY CONTROLLED RELEASE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY IMMEDIATE RELEASE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY IMMEDIATE RELEASE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY IMMEDIATE RELEASE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY IMMEDIATE RELEASE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY IMMEDIATE RELEASE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY IMMEDIATE RELEASE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY PRIVATE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY PRIVATE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY PRIVATE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY PRIVATE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY PRIVATE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY PRIVATE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY PUBLIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY PUBLIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY PUBLIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY PUBLIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY PUBLIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY PUBLIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY ONLINE PHARMACY, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY ONLINE PHARMACY, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY MARKETPLACES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY MARKETPLACES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY MARKETPLACES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY MARKETPLACES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY MARKETPLACES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY MARKETPLACES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY SPECIALTY ONLINE PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY SPECIALTY ONLINE PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY SPECIALTY ONLINE PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY SPECIALTY ONLINE PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY SPECIALTY ONLINE PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY SPECIALTY ONLINE PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY RETAIL PHARMACY, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY CHAIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY CHAIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY CHAIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY CHAIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 241. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY CHAIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 242. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY CHAIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 243. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY INDEPENDENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 244. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY INDEPENDENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 245. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY INDEPENDENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 246. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY INDEPENDENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 247. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY INDEPENDENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 248. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY INDEPENDENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 249. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 250. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 251. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY HOMECARE SETTINGS, 2018-2024 (USD MILLION)
  • TABLE 252. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY HOMECARE SETTINGS, 2025-2032 (USD MILLION)
  • TABLE 253. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY HOMECARE SETTINGS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 254. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY HOMECARE SETTINGS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 255. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY HOMECARE SETTINGS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 256. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY HOMECARE SETTINGS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 257. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY HOMECARE SETTINGS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 258. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY HOMECARE SETTINGS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 259. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY ASSISTED LIVING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 260. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY ASSISTED LIVING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 261. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY ASSISTED LIVING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 262. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY ASSISTED LIVING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 263. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY ASSISTED LIVING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 264. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY ASSISTED LIVING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 265. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY PRIVATE HOMECARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 266. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY PRIVATE HOMECARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 267. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY PRIVATE HOMECARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 268. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY PRIVATE HOMECARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 269. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY PRIVATE HOMECARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 270. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY PRIVATE HOMECARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 271. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 272. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 273. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 274. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 275. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 276. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 277. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 278. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 279. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY GENERAL HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 280. GLOBAL INSOMN